The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and safely — improve lung function in people with idiopathic pulmonary fibrosis (IPF), outperforming all lower doses in a Phase 2a trial. Three-month data from the INTEGRIS-IPF trial (NCT04396756)…
Highest Dose Bexotegrast Found to Improve Lung Function in IPF
The Pulmonary Fibrosis Foundation (PFF) is set to present the 13th edition of “Broadway Belts for PFF!” — an annual glitzy affair that has become the nonprofit’s single-largest fundraiser — on March 6. The gala, which also seeks to heighten awareness of pulmonary fibrosis (PF), will take place…
Minutes after I’m wheeled into the operating room, everyone stops — a timeout. Lying on my back with an awesome view of the ceiling, the calm and quiet of the room are very noticeable. I’d been connected to various leads, used to monitor everything from my heart rhythm to my…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis in a mouse model of the disease, its developer, Kinarus Therapeutics, reported. When KIN001 was given with Esbriet, an approved treatment, the reduction in fibrosis was even greater than…
The Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary fibrosis (PF) has enrolled its last patient. Recruitment finished sooner than anticipated, according to INOpulse developer Bellerophon Therapeutics. Top-line results are expected later this year and it’s hoped they will support efforts on…
Shortly after I was diagnosed with idiopathic pulmonary fibrosis (IPF), I was on a walk and spotted a leaf in the shape of a heart. For some reason, the beauty of it struck me. It was a sign; nature had left me a message. I collected the leaf and…
New Year’s resolutions are an annual tradition for many of us. We make promises to ourselves to do something better in the year. But this year, I’ve decided to do something different: Instead of resolutions, I plan to make new memories. Why make resolutions I know I can’t keep? After…
A protein called DACT2 alleviated signs of lung scarring in mouse models of idiopathic pulmonary fibrosis (IPF), researchers reported. In tests in cells, DACT2 was found to work by suppressing glycolysis, an energy-producing metabolic process that is overactive in myofibroblasts, the cells involved in excess scar tissue formation in IPF.
Unlike members of the band Green Day, I could happily live through an entire year of Septembers. Januarys though? Wake me up when that ends. I always find myself exhausted and burnt out this time of year. I used to chalk it up to seasonal depression, but it’s…
A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules that would inhibit a protein called transglutaminase 2 (TG2), which plays a key role in fibrosis, or tissue scarring. Preclinical…
